111 - EFFICACY AND SAFETY OF UPADACITINIB INDUCTION THERAPY IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE CROHN¿S DISEASE: RESULTS FROM A RANDOMIZED PHASE 3 U- EXCEL STUDY Edward V. Loftus; Jean-Frederic Colombel; Ana Paula Lacerda; Laurent Peyrin-Biroulet; Geert D¿Haens; Remo Panaccione; Walter Reinisch; Edouard Louis; Minhu Chen; Hiroshi Nakase; Susan Greenbloom; George DuVall; Yuri Sánchez González; Mohamed-Eslam F. Mohamed; Susan Rhee; Tian Feng; Elena Dubcenco; Julián Panés;

118 - EFFICACY OF UPADACITINIB DOSE ESCALATION IN A PHASE 3 LONG-TERM EXTENSION ULCERATIVE COLITIS STUDY Remo Panaccione; Millie Long; Raja Atreya; Hiroshi Nakase; Wen Zhou; Xuan Yao; Dapo Ilo; Geert D¿Haens; Maria Dolores Martín Arranz;

117 - 52-WEEKS RISANKIZUMAB SUBCUTANEOUS MAINTENANCE DOSING IS EFFICACIOUS AND WELL TOLERATED IN PATIENTS WITH MODERATE TO SEVERE CROHN¿S DISEASE WHO HAD DELAYED RESPONSE TO 12-WEEKS IV RISANKIZUMAB INDUCTION Geert D¿Haens; Remo Panaccione; Julián Panés; Tadakazu Hisamatsu; Peter Bossuyt; Silvio Danese; Ezequiel Neimark; Alexandra Song; Xiaomei Liao; Kori Wallace; Javier Zambrano; W Rachel Duan; Kristina Kligys; Marla Dubinsky;